Odyssey Health, Inc. (ODYY) Targeting Achievement of

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
251
Odyssey Health, Inc. (ODYY) Targeting Achievement of Important Milestones, as It Progresses Clinical Trials of Novel Concussion Drug

- Odyssey Health is focused on developing life-saving medical products and pharmaceutical assets that offer a technological and clinical advantage
- The company is developing the CardioMap Heart Monitoring and Screening Device and the Save-a-Life choking rescue device
- Its drug-device combination is intended to get PRV-002, Odyssey’s novel treatment for concussion, to the brain rapidly after concussion
- In an interview with RedChip Companies CEO Dave Gentry, Odyssey CEO Michael Redmond outlined the timelines under which the company is operating as it eyes the commercialization of its novel drug candidate

Medical company Odyssey Health (OTC: ODYY) is working to provide life-saving medical solutions that offer clinical advantages to unmet medical needs. The company boasts a repertoire of several products that include the CardioMap Heart Monitoring and Screening Device and the Save-a-Life choking rescue device, both of which are in development and are, therefore, not yet commercially available, as well as a novel breath-propelled nasal delivery device designed to deliver the company’s novel treatment for concussion, PRV-002.

Nasal Delivery Device

The nasal delivery device, which was the subject of a patent application filed last fall (https://nnw.fm/s5IZK ), is part of a drug-device combination that is being used in Odyssey’s ongoing Phase I clinical trial investigating how well PRV-002 is tolerated by healthy human subjects. “It’s a small device that essentially delivers a powdered drug through the upper chambers of the nasal cavity. The drug crosses the blood-brain barrier within 5 minutes and spreads out throughout the brain within 30 minutes, reversing the effects of a concussion,” explained Odyssey CEO Michael Redmond in a recent interview with RedChip Companies CEO Dave Gentry (https://nnw.fm/M2J7G ).

The device provides Odyssey with the opportunity to get PRV-002 into the brain rapidly after a concussion, a factor that, coupled with the drug’s safety profile and lack of adverse side effects as indicated by extensive animal trials and initial results from a section of the participants in the Phase I clinical trial, will be instrumental to the company’s success in its clinical trials.

PRV-002 Novel Drug Candidate

Developed by two neuroscientists, one of whom has a background as a toxicologist, PRV-002 is a compound that Redmond described as a drug cocktail containing three new, proprietary elements that have three mechanisms of action. “Between the two of them, having both toxicology and neurological backgrounds, they created an extremely safe drug compound. We did animal studies that show even at 200 times what we believe to be the dosing, there’s still no toxicity. So, it’s an extremely safe drug, and the efficacy in the animal models is very strong. We have confidence that this will translate into humans,” Redmond continued.

The PRV-002 drug is designed to be administered as close to a concussion event as possible, with quicker administration leading to better results. Odyssey has established that there is a window of at least six hours within which the drug shows greater efficacy, if administered.

To boost the chances of greater efficacy from quick administration, the PRV-002 drug candidate is available as a dry powder with a long shelf life and does not require special handling or refrigeration. For this reason, it can sit on the sidelines of any football game or sporting event. In addition, soldiers, who are at great risk of suffering blunt trauma from explosives’ shockwaves, bullet penetration, and violent impact, can store it in their backpacks, while emergency response teams can keep it in their ambulances or emergency rooms (“ERs”).

When asked how quickly the company expects to begin Phase II clinical trials given the ongoing Phase I clinical trial, Redmond noted, “When we have the Phase I data, we can actually start a Phase II trial in Australia immediately. We have a site set to start a Phase II trial in Australia, likely in the October timeframe. We want to do some of the Phase II or most of it in the U.S., and that requires FDA approval. We have reached out to the FDA to set up that meeting, and hopefully, we’ll have a meeting with the FDA where we can provide our Phase I data in the summer timeframe.”

The company is in discussions with the military in the U.S. to undertake the Phase II study at some of the military sites that experience a large number of concussions and has, in fact, formed a Military Advisory Board to help it achieve this goal (https://nnw.fm/KAH6j ). Odyssey expects to “be in the U.S. Phase II [clinical trial stage] this year, probably in the fourth quarter,” subject to FDA approval.

Strategic Approach

Odyssey has strategically planned its Phase II trial to ensure it collects data as soon as the study commences. According to Redmond, the ability to gather data is a function of the number of concussed patients, meaning the company has to set trials at sites that report a high number of concussions. For example, the military has at least two sites that experience over 100 concussions a month. And by setting up the trials at these sites, the company expects to start collecting data immediately upon the start of the trial.

Redmond also highlighted the subsequent phases of its drug development journey, noting that the drug could be available for commercialization to Special Populations – a group of people, in this case, the military, that experiences concurrent disease states (https://nnw.fm/Z305G ) – immediately after a successful Phase II trial. That’s because there is currently no FDA-approved treatment for concussion. To facilitate this milestone, Odyssey would be open to partnerships for commercialization, marketing, and distribution.

For more information, visit the company’s website at https://odysseygi.com/.

NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://nnw.fm/ODYY

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer




Odyssey Group Intl Inc (ODYY) Stock Research Links

ODYY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Carolina Pines Tackles Rural Healthcare Myths on TV

Updated Category News Views 14

Rural Healthcare Battles the Big City Myth Picture this: you're in a tiny town where everyone knows your dog's name, but some think you've got to head to the city for top-notch medical care. That's where Carolina Pines Regional Medical Center steps in. They’ve snagged a spot on 'All Access with Andy Garcia', shining a light on how investments in tech and talent keep...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 52

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
WirelessCar Rebrands to Reinforce Connected Mobility Vision

Updated Category News Views 0

Evolving Identity for Changing Times Let’s dive right into it—WirelessCar, a name that’s struck chords in the automotive trenches for ages, is taking a bold step by unveiling a new brand identity. Now, don’t roll your eyes just yet. This isn’t another company tapping the rebranding siren for the heck of it. We’re talking about a company that’s been in the...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Fortvita's Zybrivo Gains CHMP Nod: A European Leap

Updated Category News Views 0

It's not every day you're reading about a biotech making a ground-breaking shift off Chinese shores, but Fortvita's latest breakthrough is worth noting. Their fancy immunotherapy, Zybrivo® (sintilimab), just snagged a nod from the CHMP, Europe's committee that guides many on the medicinal merry-go-round. This isn't just your run-of-the-mill nod either. We're talking...

Continue Reading
Sivers Semiconductors: Strategy Behind 2027 AGM Plans

Updated Category News Views 46

Setting the Stage for a Crucial Year Ah, the dance of corporate governance—an arena where maneuvering is an art. Sivers Semiconductors AB, a name that's becoming synonymous with innovation in the photonics and wireless solutions sector, is prepping for its 2027 Annual General Meeting. Ahead of this pivotal event, they're forming a Nomination Committee to shape future...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 138

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 370

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 0

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 123

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading

Top 5 Most Recently Viewed Articles

Cloudastructure's Innovative AI Prevents Crime with 98% Success

Updated Category News Views 134

Cloudastructure's Impressive AI-Driven Crime Prevention Cloudastructure, Inc. (Nasdaq: CSAI) has emerged as a frontrunner in AI surveillance and remote guarding, successfully achieving an impressive crime deterrence rate exceeding 98% within a short span. This significant accomplishment, highlighted during the early months of the year, underscores the platform's...

Continue Reading
Apollo Global Management's Growth Strategy and Investor Outlook

Updated Category News Views 576

Barclays kept its Overweight rating on Apollo Global Management (NYSE: APO) back in early 2024, setting a price target of $128. This came as traders braced for the highly anticipated 2024 Investor Day where Apollo was expected to reveal its medium and long-term strategic objectives. Key numbers like assets under management (AUM), fundraising capabilities, fee-related...

Continue Reading
Leadership Changes at BlackLine: A New Era Unfolds Ahead

Updated Category News Views 367

BlackLine's Leadership Transition: A Strategic Move BlackLine, Inc. (Nasdaq: BL), the leading platform driving digital finance transformation, has announced a pivotal leadership transition aimed at enhancing its operational framework and growth trajectory. Therese Tucker's Evolving Role In a move that reflects the company's commitment to its strategic objectives, Therese...

Continue Reading
Hargreave Hale AIM VCT PLC Updates on Share Transactions

Updated Category News Views 41

Hargreave Hale AIM VCT PLC Engages in Strategic Share Acquisition Hargreave Hale AIM VCT PLC is focused on boosting shareholder value by taking strategic actions in the market. Recently, the company made a noteworthy announcement regarding its shares. Details of the Share Acquisition On a significant date, Hargreave Hale AIM VCT PLC acquired 367,436 ordinary shares at a...

Continue Reading
Tanmiah's Commitment to Sustainability Shines at Halal Forum

Updated Category News Views 156

Tanmiah's Role at the Makkah Halal Forum Tanmiah Food Company (TADAWUL: 2281, "Tanmiah"), a frontrunner in halal protein, recently highlighted its dedication as a Platinum Sponsor at the Makkah Halal Forum. This event serves as a crucial platform for showcasing the best halal services and products, allowing Tanmiah to demonstrate its leadership and innovative edge in the...

Continue Reading